AIMT

PALFORZIA®

Peanut Allergy | POSEIDON

Phase 3 (Data)

Exp Date

H2 2021

Amp Volatility Score

Catalyst Info & Data Links

TITLE: PALFORZIA® in Peanut Allergy - Phase 3 Data

  • ClinicalTrial.gov (NCT03736447): Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)


WHAT IS THE CATALYST EVENT?


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • H2 2021


PRIOR DATA

PRESS RELEASES


Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon